Weranja Ranasinghe
Overview
Explore the profile of Weranja Ranasinghe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lim S, Soroush S, Wei G, Harper M, Donnellan S, Ranasinghe W
ANZ J Surg
. 2025 Jan;
PMID: 39876634
Backgrounds: PSA screening is advocated in men with a life expectancy of >10 years. With a rising mean life expectancy of 81 years in Australia, many men in their 70s...
2.
Sii S, Papa N, Yiu T, Tempo J, Qu L, Perera M, et al.
BJU Int
. 2024 Nov;
PMID: 39607059
Objective: To investigate the relationship between the prostate-specific antigen (PSA) free-to-total ratio (FTR) and International Society of Urological Pathology Grade Group ≥2, clinically significant prostate cancer (csPCa) in men with...
3.
Qin S, Chislett B, Ischia J, Ranasinghe W, De Silva D, Coles-Black J, et al.
BJUI Compass
. 2024 Sep;
5(9):813-821.
PMID: 39323919
Introduction: ChatGPT (generative pre-trained transformer [GPT]), developed by OpenAI, is a type of generative artificial intelligence (AI) that has been widely utilised since its public release. It orchestrates an advanced...
4.
Lim S, Lim K, Qu L, Ranasinha S, Dat A, Brown M, et al.
BJUI Compass
. 2024 Aug;
5(8):748-760.
PMID: 39157165
Introduction And Objectives: Voiding dysfunction remains a common side effect postprostate biopsy leading to significant morbidity. Alpha blockers have emerged as a potential therapeutic option to mitigate this risk, with...
5.
Brennen W, Le Magnen C, Karkampouna S, Anselmino N, Bock N, Choo N, et al.
Prostate
. 2024 Mar;
84(7):623-635.
PMID: 38450798
Background: There are relatively few widely used models of prostate cancer compared to other common malignancies. This impedes translational prostate cancer research because the range of models does not reflect...
6.
Lim K, Chu K, Rajarubendra N, Huang J, Pook D, Manohar P, et al.
Bladder (San Franc)
. 2024 Jan;
10:e21200013.
PMID: 38163008
Objectives: Although neoadjuvant chemotherapy (NAC) has been demonstrated to have significant benefits to survival in patients with muscle-invasive bladder cancer (MIBC), the current utilization of NAC in Australia is unknown....
7.
Dat A, Wei G, Knight S, Ranasinghe W
BJUI Compass
. 2023 Oct;
4(6):622-658.
PMID: 37818029
Objective: To systematically review and critically appraise all treatment options for localised prostate cancer in renal transplant candidates and recipients. Method: A systematic review was conducted adhering to PRISMA guidelines....
8.
Lim K, Alberto M, Ranasinghe W
Curr Opin Support Palliat Care
. 2023 Oct;
17(4):315-323.
PMID: 37788147
Purpose Of Review: Recently, there has been emerging interest in the treatment of primary tumours in metastatic prostate cancer based on major trials that have provided evidence for radiation therapy...
9.
Lim K, Liew A, Ling Z, Ranasinghe W, McCahy P
J Clin Med
. 2023 Jul;
12(14).
PMID: 37510922
With increases in the aging population, conditions affecting older people and relevant surgical techniques are becoming more pertinent. Modified supine percutaneous nephrolithotomy (PCNL) is increasingly being adopted. There are limited...
10.
Wei G, Ranasinghe W, Evans M, Bolton D, Dodds L, Frydenberg M, et al.
BJU Int
. 2023 Apr;
131 Suppl 4:36-42.
PMID: 37099558
Objective: To assess changes in diagnosis prostate cancer (PCa) grade, biopsy and treatment approach over a decade (2011-2020) at a population level within a clinical quality cancer registry. Patients And...